Back to all Current clinical trials
Back to all Current clinical trials
A drug comparison for patients with newly diagnosed with metastatic hormone-sensitive prostate cancer
The purpose of this study is to compare the effects, good or bad of an investigational product, capivasertib added to standard treatments in patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) and your cancer has low levels of a protein called PTEN (or “PTEN deficiency”).
What you need to know
Who can take part?
Patients with metastatic hormone-sensitive prostate cancer (mHSPC).
What is involved for you?
Participation in this study may continue for 4.5 years. It will involve seeing the doctor and coordinator for study visits every 2-4 weeks for physical exams, ECG's, blood tests, tumour assessments (ie-CT scans). You will be required to take oral medicine most days of the study, and do some self assessments of your side effects.
